Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04195451 · ClinicalTrials.gov registry record · NA

Re-Energize Fontan

A NA study of Single-ventricle, sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT04195451: Recruiting NA study of Single-ventricle, sponsored by Stanford University.

NCT04195451 is a NA study of Single-ventricle that is actively recruiting participants, run by Stanford University. The registered enrollment target is 150 participants, above the 78-participant average among 17 other Single-ventricle trials with a reported enrollment target (92% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04195451, a NA study of Single-ventricle, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

Survival of children with single ventricles ("half a heart") beyond the neonatal period has increased dramatically with the staged Fontan palliation. Yet, long-term morbidity remains high. By the age of 40, 50% of Fontan patients will have died or undergone heart transplantation. With \>1,000 Fontan palliations performed in the US annually, there is a burgeoning population of Fontan patients at risk for progressive heart failure and death. Factors that contribute to onset and progression of heart failure in Fontan patients remain incompletely understood. However, it is established that Fontan patients have poor exercise capacity, associated with a greater risk of morbidity and mortality, in addition to decreased muscle mass, abnormal muscle function, and endothelial dysfunction contributing to disease progression. In adult patients with two ventricles and heart failure, reduced exercise capacity, muscle mass, and muscle strength are powerful predictors of poor outcomes, and exercise interventions can not only improve exercise capacity and muscle mass, but also reverse endothelial dysfunction. Limited exercise interventions in children with congenital heart disease have demonstrated that exercise is safe and effective; however, these studies have been conducted in small, heterogeneous groups, and most had few Fontan patients. Furthermore, none of these interventions have studied the impact of exercise on muscle mass or mitochondrial function, or endothelial function. The investigators propose a milestone-driven, randomized controlled trial in pediatric Fontan patients to test the hypothesis that a live-video-supervised exercise (aerobic + resistance) intervention will improve cardiac and physical capacity; muscle mass, strength and function; and endothelial function. The investigators' ultimate goal is the translation of this model to clinical application as an "exercise prescription" to intervene early in pediatric Fontan patients and decrease long-term morbidity an

Primary Outcome

In Fontan patients, peak VO2 is a powerful predictor of poor outcomes. The subjects will undergo progressive cardiopulmonary exercise testing with continuous monitoring by 12-lead EKG and gas exchange by measuring breath-to-breath ventilation. Exercise capacity will be measured by a cardiopulmonary exercise test to obtain the peak VO2

Conditions Studied

Interventions

  • OTHER Live-Video-Supervised Exercise Intervention
  • OTHER Usual Care then Live-Video Supervised Exercise Intervention

Study Locations (1)

California

  • Stanford University, Lucile Packard Children Hospital - Palo Alto

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2020-08-06
Est. Completion 2026-03-01
Phase NA
Stanford University

1,744 total trials

What NCT04195451 shows while recruiting

NCT04195451 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 78-participant average among 17 other Single-ventricle trials with a reported enrollment target (92% higher).

The record links to 1 condition, with Single-ventricle appearing as the primary indexed condition, and to 2 interventions - of which Live-Video-Supervised Exercise Intervention is the first listed.

NCT04195451 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04195451 about?

NCT04195451 is a clinical study titled "Re-Energize Fontan". Survival of children with single ventricles ("half a heart") beyond the neonatal period has increased dramatically with the staged Fontan palliation. Yet, long-term morbidity remains high. By the age of 40, 50% of Fontan patients will have died or undergone heart transplantation. With \>1,000 Fontan...

What is the current status of trial NCT04195451?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2020-08-06. Estimated completion is 2026-03-01.

What conditions does trial NCT04195451 study?

This clinical trial studies the following conditions: Single-ventricle.

What interventions are being tested in trial NCT04195451?

The interventions under investigation include: Live-Video-Supervised Exercise Intervention (OTHER), Usual Care then Live-Video Supervised Exercise Intervention (OTHER).

Who is sponsoring clinical trial NCT04195451?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04195451 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Single-ventricle

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04195451's enrollment target sits among peer trials

150 3rd of 17 higher than 15 of 17 other Single-ventricle trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Single-ventricle trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04195451, the US trial registry maintained by the National Library of Medicine. NCT04195451 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.